Theranos Gets Rid of 41% of Staff
As if things couldn’t get worse for Theranos, the news came today that the company is cutting nearly 41% of its positions (155 employees), with only 220 staff remaining. According to Bloomberg those employees who remain will work on Theranos’ minilab product, which has not yet received the seal of approval from FDA.
Theranos laid off 340 employees last October, and back in July CMS banned the company’s CEO Elizabeth Holmes from operating any lab for two years (Read the list of CMS sanctions against Theranos).
Related Articles
-
There are concerns over the accuracy of direct-to-consumer tests.
-
In a Today Show interview, Elizabeth Holmes voices responsibility felt as a result of company problems.
-
A company statement aims to set the record straight.
-
Agency sanctions include a monetary penalty and revocation of the lab’s CLIA certificate.
-
Mainstream media attention catapulted the company to the center of controversy for its finger-prick lab tests. Now FDA has taken issue with the company’s complaint handling and design validation.
About The Author
MedTech Intelligence Staff
The MedTech Intelligence staff consists of freelance journalists and industry contributing writers with decades of experience in covering medical device issues under the categories of business, market trends, product development, quality, regulatory, and operations.
You can contact our writing staff via our Contact Page.